hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06308666 id: 46091 briefTitle: Performance of DAILIES TOTAL1 Daily Disposable Contact Lenses in Habitual Soft Lens Wearers Who Report Substantial Digital Device Use acronym: FOX overallStatus: RECRUITING date: 2024-03-18 date: 2024-07-18 date: 2024-07-18 date: 2024-03-13 date: 2024-03-22 name: University of Waterloo class: OTHER name: Alcon Research briefSummary: The purpose of this study is to evaluate the performance of DAILIES TOTAL1 daily disposable contact lenses with regards to subjective symptoms (comfort, dryness, vision) in lens wearers who use identify themselves as substantial digital device users (at least eight hours of digital device use per day). conditions: Myopia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Delefilcon A contact lenses measure: Subjective Rating of Comfort After 8 Hours or More of Digital Device Use measure: Subjective Rating of Dryness After 8 Hours or More of Digital Device Use measure: Subjective Rating of Clarity of Vision After 8 Hours or More of Digital Device Use sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Centre for Ocular Research & Education status: RECRUITING city: Waterloo state: Ontario zip: N2L 3G1 country: Canada name: Jill Woods, McOptom role: CONTACT phone: 519-888-4567 phoneExt: 36743 email: jwoods@uwaterloo.ca name: Lyndon Jones, PhD, FCoptom role: PRINCIPAL_INVESTIGATOR lat: 43.4668 lon: -80.51639 hasResults: False
nctId: NCT06308653 id: PSIL301 briefTitle: Psilocybin for Major Depressive Disorder (MDD) acronym: uAspire overallStatus: RECRUITING date: 2024-03-05 date: 2025-04 date: 2026-04 date: 2024-03-13 date: 2024-03-26 name: Usona Institute class: OTHER briefSummary: Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period. conditions: Depressive Disorder, Major studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to receive Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo under double-blind conditions. After the initial 6-week Double-blind Period, all participants will proceed into a 1-year Follow-up Period. During this 1-year Follow-up Period, eligible participants who meet pre-determined criteria may be offered open-label Psilocybin 25 mg in the context of a "Set and Setting" (SaS) Protocol. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The following roles will be blinded to the treatment group assignment in the Double-blind Period during the trial: Participant, Investigator, Site Personnel, Facilitators, Efficacy Raters (including Site Raters, Participant Raters, and Central Raters), Contract Research Organization (CRO) Staff, and Sponsor.
Full blinding of trial personnel, Sponsor, and participants will be maintained until database lock at the conclusion of the trial. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 240 type: ESTIMATED name: Psilocybin 25 mg name: Inactive Placebo name: Psilocybin 5 mg name: Psychosocial Support measure: Change in central rater Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to Trial Day 43 measure: Change in central rater Clinical Global Impression-Severity (CGI-S) total score from Baseline to Trial Day 43 measure: Change in on-site rater administered Sheehan Disability Scale (SDS) score from Baseline to post-dose Day 43 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mountain View Clinical Research status: RECRUITING city: Denver state: Colorado zip: 80209 country: United States name: Brian Johnson role: CONTACT phone: 720-941-9363 phoneExt: 703 email: Brian@mtnresearch.com name: David Weiss, MD role: PRINCIPAL_INVESTIGATOR lat: 39.73915 lon: -104.9847 facility: Innovative Clinical Research, Inc. status: RECRUITING city: Lauderhill state: Florida zip: 33319 country: United States name: Shelbie Bobrow role: CONTACT phone: 954-769-1397 email: sbobrow@segaltrials.com name: Louis Sotolongo role: CONTACT phone: 954-769-1397 email: lsotolongo@segaltrials.com name: Rishi Kakar, MD role: PRINCIPAL_INVESTIGATOR lat: 26.14036 lon: -80.21338 facility: Cedar Clinical Research status: RECRUITING city: Draper state: Utah zip: 84020 country: United States name: Jane Bjorklund role: CONTACT phone: 801-369-4219 email: jane.bjorklund@numinus.com name: Reid Robison, MD role: PRINCIPAL_INVESTIGATOR lat: 40.52467 lon: -111.86382 facility: Cedar Clinical Research, Inc. status: RECRUITING city: Murray state: Utah zip: 84107 country: United States name: Jane Bjorklund role: CONTACT phone: 801-369-4219 email: jane.bjorklund@numinus.com name: Paul Thielking, MD role: PRINCIPAL_INVESTIGATOR lat: 40.66689 lon: -111.88799 hasResults: False
nctId: NCT06308640 id: ORTH 11-23 2097 briefTitle: Evaluation of Maxillary Molar Distalization With Two Bone Supported Protocols Using Cone Beam Computed Tomography overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-10 date: 2026-01-10 date: 2026-01-10 date: 2024-03-13 date: 2024-03-13 name: Tanta University class: OTHER briefSummary: The goal of this clinical trial is to to evaluate and compare the skeletal and dental changes of bone supported Fast Back and bone supported modified Leaf Spring Self-Activated Expander in bilateral distalization of maxillary molars using CBCT in Egyptian people. The main question it aims to answer are: • If bone supported Fast Back and bone supported modified Leaf Spring Self-Activated Expander will be effective in bilateral distalization of maxillary molars
Researchers will compare between bone supported Fast Back appliance and bone supported modified Leaf Spring Self-Activated and see if they will be effective in maxillary molars distalization. conditions: Class II Malocclusion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The purpose of this study is to evaluate and compare the treatment effects of two bone supported protocols for bilateral distalization of maxillary molars in patients exhibiting class II pattern using Fast Back appliance and modified Leaf Spring Self-Activated Expander primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 20 type: ACTUAL name: Insertion of the device intraorally measure: 3D Dental and skeletal Cephalometric Measurements measure: 2D Dental and skeletal Cephalometric Measurements sex: ALL minimumAge: 14 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Faculty of Dentistry city: Tanta state: Gharbia zip: 6620010 country: Egypt lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06308627 id: K2022-03-074 briefTitle: A One-year Trajectory of Depression Status Changes in Elderly Patients With MCI and SD: a Longitudinal Cohort Study overallStatus: RECRUITING date: 2023-06-01 date: 2024-07-01 date: 2024-07-01 date: 2024-03-13 date: 2024-03-13 name: Fujian Medical University class: OTHER briefSummary: The purpose of this study is to investigate the one-year trajectory of changes in depression status in elderly patients with mild cognitive impairment and subthreshold depression, and to explore relevant risk factors for predicting changes in depression status. This one-year prospective longitudinal follow-up study involved 400 (expected) subjects who met the diagnostic criteria for mild cognitive impairment combined with subthreshold depression in the elderly, and their depressive status was assessed using the Geriatric Depression Scale (GDS). Follow up monitoring of depression status at 6 and 12 months. Obtain factors related to changes in depressive status (such as age, gender, education level, cognitive function, anxiety level, sleep status, social support, psychological resilience, social network, etc.). By studying the longitudinal trajectory of depression status in elderly patients with mild cognitive impairment and subthreshold depression, a multi state Markov model with time and state discreteness is constructed, namely: State 1 (normal); State 2 (subliminal depression); State 3 (mild depression); State 4 (moderate depression); State 5 (severe depression). Deeply explore and analyze the impact of certain factors and indicators on the transition between states, and estimate the probability of transition between states. conditions: Mild Cognitive Impairment conditions: Subthreshold Depression conditions: Older Adults studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED measure: Depressive state measure: General information of patients measure: Cognitive measure: Cognitive measure: Activity of Daily Living measure: Anxiety measure: Social Function measure: Social Function measure: Sleep Quality measure: Resilience sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian provincial hospital status: RECRUITING city: Fuzhou state: Fujian zip: 350000 country: China name: Hong Li role: CONTACT phone: 18120826271 email: leehong99@126.com lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06308601 id: 23-12.1T/60 briefTitle: The Effect of Laughter Yoga on Loneliness, Anger and Salivary Cortisol Levels in Visually Impaired Individuals overallStatus: ENROLLING_BY_INVITATION date: 2024-05-16 date: 2024-06-04 date: 2024-06-27 date: 2024-03-13 date: 2024-03-13 name: Ege University class: OTHER briefSummary: Purpose: This project aimed to examine the effects of laughter yoga, which is accepted as an international nursing initiative, on loneliness, anger and salivary cortisol levels in visually impaired individuals. When the national and international literature was examined, no project was found that measured the results of laughter yoga as an intervention for visually impaired individuals. For this reason, planning an original project in this field aims to contribute to the literature. Thanks to the evidence obtained, laughter yoga, an innovative approach, can be disseminated in institutions and organizations serving visually impaired individuals as an evidence-based practice that can improve the social skills of individuals.
Method and Expected Result: The project was planned in a randomized controlled, pre-test post-test, single-blind follow-up consultancy design. With this initiative, a social rehabilitation environment will be provided for visually impaired individuals by taking an approach based on respect, understanding and awareness. Laughter yoga is expected to reduce the level of anger and loneliness in visually impaired individuals. At the same time, laughter yoga is expected to reduce cortisol levels, which are known to increase when faced with stress factors, and increase serotonin, which is associated with happiness and vitality, and endorphine, known as the body's natural painkiller. With laughter yoga sessions, a social environment will be created where visually impaired individuals will have an active and independent experience. Thanks to the expected evidence, laughter yoga can be popularized both in visually impaired individuals and in individuals with other disabilities. Within the scope of protecting and improving health, laughter yoga can be planned to be carried out as a routine nursing practice in disabled centers. Thus, by creating an environment where visually impaired individuals and nurses come together, a more accessible health service will be provided to individuals with special needs. conditions: Nursing Caries conditions: Laughter conditions: Visual Impairment conditions: Loneliness conditions: Anger studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Research Population: The population of this research is the visually impaired individuals who received service from the Disabled Department within the Ataturk Provincial Public Library in Konak district of Izmir province between 2023-2024.
Research Sample: In the research, "G. Using the "Power-3.1.9.7" program, the sample size of the study was calculated at a 95% confidence level before the data collection phase. The standardized effect size was found to be 0.90 when calculated based on the mean and standard deviation values of previous studies. As a result, the minimum number of samples was calculated as 28 for each group with a 95% confidence level, 0.05 alpha value, 0.90 intervention effect size and 95% theoretical power. It is aimed to reach 56 people in total. Considering that there will be a 20% case loss in experimental studies in the literature (Pan, et al., 2019), the number of samples was determined as 60 (30 interventions; 30 controls). primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Statistical evaluation of the research results will be made by an expert other than the researcher. whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Laughter yoga measure: salivary cortisol test measure: UCLA(University of California, Los Angeles) Loneliness Scale measure: Trait Anger Scale sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Ege University city: Bornova state: İ̇zmi̇r zip: 35030 country: Turkey lat: 38.47921 lon: 27.2399 hasResults: False
nctId: NCT06308588 id: 2024-0054 id: NCI-2024-02121 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2027-05-01 date: 2029-05 date: 2024-03-13 date: 2024-04-29 name: M.D. Anderson Cancer Center class: OTHER name: Novartis Pharmaceuticals briefSummary: To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL. conditions: Philadelphia Chromosome-Positive conditions: Acute Lymphoblastic Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Blinatumomab name: Asciminib measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Nicholas Short, MD role: CONTACT phone: 713-563-4485 email: nshort@mdanderson.org name: Nicholas Short, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06308575 id: 2023-0771 id: NCI-2024-02155 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2026-11-30 date: 2028-11-30 date: 2024-03-13 date: 2024-03-13 name: M.D. Anderson Cancer Center class: OTHER name: Elevar Therapeutics briefSummary: To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied. conditions: Metastatic Olfactory Neuroblastoma conditions: Recurrent Olfactory Neuroblastoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: Rivoceranib measure: Safety and Adverse Events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Luana Guimaraes De Sousa, MD role: CONTACT phone: 832-728-7849 email: lgsousa@mdanderson.org name: Luana Guimaraes De Sousa, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06308562 id: 23-010717 briefTitle: Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-08 date: 2024-08 date: 2024-03-13 date: 2024-04-04 name: Mayo Clinic class: OTHER briefSummary: The objective of this study is to determine if using Fuzzy Wale compression stockinett can assist in reducing the healing time and decrease costs in trastibial amputation patients as compared to standard of care treatment compression stocking. conditions: Peripheral Arterial Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: Fuzzy Wale Compression Stockinet measure: Surgical site infection measure: Wound dehiscence measure: Days on negative pressure wound therapy measure: Pain control measure: Time to prosthetic fitting measure: Length of hospital stay sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic city: Rochester state: Minnesota zip: 55905 country: United States name: Vascular Research Team role: CONTACT phone: 507-538-7425 name: Matthew Melin, M.D. role: CONTACT phone: (507) 266-6717 email: Melin.Matthew@mayo.edu name: Matthew Melin, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06308549 id: 2023.0714 briefTitle: MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY) acronym: MyREMEDY overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-07 date: 2025-07 date: 2024-03-13 date: 2024-03-13 name: Maartje de Wit class: OTHER name: Juvenile Diabetes Research Foundation name: King's College London name: University of Malaga name: Forschungsinstitut der Diabetes Akademie Mergentheim briefSummary: In the MyREMEDY study the investigators research whether the MyDiaMate self-help application is effective in strengthening the mental health of adults with type 1 diabetes in comparison with care as usual. The MyREMEDY study takes place in four countries: The Netherlands, United Kingdom, Spain, and Germany. conditions: Type 1 Diabetes conditions: Diabetes Distress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 660 type: ESTIMATED name: MyDiaMate measure: Diabetes Distress measure: Emotional well-being measure: Psychological self-efficacy in relation to diabetes measure: Social Engagement measure: Fatigue measure: HbA1c measure: Time in/above/below range measure: Events of ketoacidosis/severe hypoglycaemia measure: MyDiaMate usage data sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Forschungsinstitut Diabetes-Akademie Bad Mergentheim city: Bad Mergentheim state: Baden-Württemberg zip: 97980 country: Germany name: Dominic Ehrmann role: CONTACT phone: +4979319613839 email: info@fidam.de name: Dominc Ehrmann role: PRINCIPAL_INVESTIGATOR name: Gina Lehmann role: SUB_INVESTIGATOR name: Norbert Hermanns role: PRINCIPAL_INVESTIGATOR lat: 49.4925 lon: 9.77361 facility: Amsterdam UMC city: Amsterdam state: Noord-Holland zip: 1081HV country: Netherlands name: Theresa Mohr, MSc role: CONTACT phone: +31205669111 email: myremedy@amsterdamumc.nl name: Maartje de Wit, Dr. role: PRINCIPAL_INVESTIGATOR name: Theresa Mohr, MSc. role: SUB_INVESTIGATOR lat: 52.37403 lon: 4.88969 facility: Universidad de Málaga city: Málaga zip: 29071 country: Spain name: Maria Teresa Anarte role: CONTACT phone: +34952131313 email: info@uma.es name: Maria Teresa Anarte role: PRINCIPAL_INVESTIGATOR lat: 36.72016 lon: -4.42034 facility: King's College London city: London zip: WC2R 2LS country: United Kingdom name: Kirsty Winkley, Dr. role: CONTACT phone: +4402078365454 email: MyREMEDY@kcl.ac.uk name: Kirsty Winkly, Dr. role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06308536 id: KY-2023-045 briefTitle: Application of Concentrated Growth Factors in Alveolar Ridge Preservation overallStatus: RECRUITING date: 2023-05-09 date: 2024-10-01 date: 2025-04-01 date: 2024-03-13 date: 2024-03-13 name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: To explore the role of CGF in the regeneration or preservation of soft and hard tissues during tooth extraction site preservation surgery. conditions: Alveolar Ridge Preservation conditions: Concentrated Growth Factor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: bone powder + collagen membrane name: bone powder + collagen membrane + CGF membrane name: bone powder mixed wih CGF gel + collagen membrane + CGF membrane name: bone powder + CGF membrane measure: the width of keratinized gingiva measure: the horizontal width (from buccal to lingual at the alveolar top ) of gingiva measure: the horizontal bone resorption of alveolar crest measure: the vertical bone resorption of alveolar crest measure: the average gray value of alveolar bone measure: Landry wound healing index measure: reduction in membrane exposure area measure: pain score sex: ALL minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: The Fourth Affiliated Hospital Zhejiang University School of Medicine status: RECRUITING city: Yiwu state: Zhejiang Procince zip: 310000 country: China name: Genying Zhuang, Master role: CONTACT phone: 13758195143 email: 20918620@zju.edu.cn lat: 29.31506 lon: 120.07676 hasResults: False
nctId: NCT06308523 id: AP303-PK-02 briefTitle: A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-06-10 date: 2024-06-30 date: 2024-03-13 date: 2024-03-13 name: Alebund Pharmaceuticals class: INDUSTRY briefSummary: The study will be a single center, double-blind, randomized, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to healthy Chinese participants. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 18 type: ESTIMATED name: AP303 150 μg name: Placebo 150 μg name: AP303 300 μg name: Placebo 300 μg measure: Cmax measure: Tmax measure: AUC0-24h measure: AUC0-last measure: AUC0-inf measure: AUC0-t measure: t1/2 measure: CL/F measure: V/F measure: Cav measure: Ctrough measure: Rac measure: Incidence and severity of adverse events measure: Incidence of laboratory abnormalities, based on hematology, clinical chemistry, coagulation and urinalysis test results measure: Effect of AP303 on ECG parameters measure: Effect of AP303 on ECG parameters measure: Effect of AP303 on ECG parameters measure: Effect of AP303 on ECG parameters measure: Effect of AP303 on ECG parameters measure: Effect of AP303 on ECG parameters measure: Vital signs measure: Effect of AP303 on physical examination result measure: body weight measure: Fasting glucose measure: Fasting lipid profile measure: Serum creatinine measure: eGFR sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False